Genomic Health (GHDX) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies Raises price Target on Genomic Health (GHDX) Following Initial 2016 Outlook
February 11, 2016 10:05 AM ESTJefferies reiterated a Hold rating on Genomic Health Inc. (NASDAQ: GHDX), and raised the price target to $25.00 (from $24.00). Consistent with commentary last month, GHDX reiterated its 2016 revenue outlook ($328M mid-pt), which implies a sharp growth acceleration on the back of full-year contributions from recent... More
Piper Jaffray Cuts Price Target on Genomic Health (GHDX) After 4Q Reports In-Line with Preliminary Results
February 11, 2016 9:15 AM ESTPiper Jaffray reiterated a Neutral rating on Genomic Health Inc. (NASDAQ: GHDX), and cut the price target to $31.00 (from $32.00), following the company's 4Q earnings report. Genomic Health announced 4Q15 revenue growth of 7.8% yoy to $74.5M, slightly above preliminary results ($73M-$74M). Management attributes... More
